Pathogenicity and Transcriptomic Profiling Revealed Activation of Apoptosis and Pyroptosis in Brain of Mice Infected

Han Li1, Bao Ying Huang2, Gao Qian Zhang3

  • 1National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China;School of Public Health, Baotou Medical College, Baotou 014040, Inner Mongolia, China.

Abstract

Insights

The SARS-CoV-2 beta variant causes brain damage by triggering innate immunity and inflammatory pathways in K18-hACE2 mice. This study reveals key mechanisms of neuropathogenicity and potential therapeutic targets for COVID-19 neurological issues.

Area of Science:

  • Neuroscience
  • Virology
  • Immunology

Background:

  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection often leads to central nervous system damage.
  • The precise mechanisms underlying SARS-CoV-2-induced neuropathology are not fully understood.

Purpose of the Study:

  • To investigate the pathways and factors involved in brain tissue damage caused by the SARS-CoV-2 beta variant (lineage B.1.351).

Main Methods:

  • K18-hACE2 and C57BL/6 mice were infected with the SARS-CoV-2 beta variant.
  • Viral replication, pathology, and brain transcriptomes were analyzed.
  • Gene Ontology (GO) analysis identified altered pathways; gene expression was validated via RT-qPCR and Western blot.

Main Results:

  • K18-hACE2 mice showed elevated viral loads and neuropathological injury in the brain.
  • Significant dysregulation of innate immunity and antiviral response genes (interferons, cytokines, TLRs) was observed.
  • Neuroinflammation, apoptosis, pyroptosis, and neuroglial activation were evident, disrupting neuronal networks.

Conclusions:

  • The SARS-CoV-2 beta variant induces neuropathogenicity through innate immune and inflammatory pathways.
  • Findings highlight potential therapeutic targets for mitigating COVID-19-related neurological dysfunction.